Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2024
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Carol D. Karp [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On February 26, 2024, Carol D. Karp, Chief Regulatory Officer, adopted a Rule 10b5-1 trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 105,000 shares of the Company’s ordinary shares until June 3, 2025. However, this plan was terminated on March 29, 2024. On March 29, 2024, Ms. Karp adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 105,000 shares of the Company’s ordinary shares until June 3, 2025.
|
| Tran B. Nguyen [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On February 26, 2024, Tran B. Nguyen, Chief Strategy Officer and Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 510,150 shares of the Company’s ordinary shares until May 15, 2025.
|
| Name | Tran B. Nguyen |
| Title | Chief Strategy Officer and Chief Financial Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | February 26, 2024 |
| Arrangement Duration | 444 days |
| Aggregate Available | 510,150 |
| Gene G. Kinney [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 13, 2024, Gene G. Kinney, President and Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 141,599 shares of the Company’s ordinary shares until June 15, 2025.
|
| Name | Gene G. Kinney |
| Title | President and Chief Executive Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 13, 2024 |
| Arrangement Duration | 459 days |
| Aggregate Available | 141,599 |
| Richard T. Collier [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 21, 2024, Richard T. Collier, director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 18,229 shares of the Company’s ordinary shares until May 22, 2025.
|
| Name | Richard T. Collier |
| Title | director |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 21, 2024 |
| Arrangement Duration | 427 days |
| Aggregate Available | 18,229 |
| Shane M. Cooke [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 21, 2024, Shane M. Cooke, director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 18,229 shares of the Company’s ordinary shares until May 22, 2025.
|
| Name | Shane M. Cooke |
| Title | director |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 21, 2024 |
| Arrangement Duration | 427 days |
| Aggregate Available | 18,229 |
| Hideki Garren [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 21, 2024, Hideki Garren, Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 90,000 shares of the Company’s ordinary shares until June 30, 2025.
|
| Name | Hideki Garren |
| Title | Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 21, 2024 |
| Arrangement Duration | 466 days |
| Aggregate Available | 90,000 |
| Lars G. Ekman [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 26, 2024, Lars G. Ekman, director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 18,229 shares of the Company’s ordinary shares until May 22, 2025.
|
| Name | Lars G. Ekman |
| Title | director |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 26, 2024 |
| Arrangement Duration | 422 days |
| Aggregate Available | 18,229 |
| Carol D. Karp February 2024 Plan [Member] | Carol D. Karp [Member] | |
| Trading Arrangements, by Individual | |
| Name | Carol D. Karp |
| Title | Chief Regulatory Officer |
| Adoption Date | February 26, 2024 |
| Rule 10b5-1 Arrangement Terminated | true |
| Termination Date | March 29, 2024 |
| Aggregate Available | 105,000 |
| Carol D. Karp March 2024 Plan [Member] | Carol D. Karp [Member] | |
| Trading Arrangements, by Individual | |
| Name | Carol D. Karp |
| Title | Chief Regulatory Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 29, 2024 |
| Arrangement Duration | 431 days |
| Aggregate Available | 105,000 |